- Home
- VRNS vs STVN Comparison
VRNS vs STVN Comparison
Compare VRNS & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRNS | STVN |
|---|---|---|
| Founded | 2004 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Containers/Packaging |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.7B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VRNS | STVN |
|---|---|---|
| Price | $46.89 | $19.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 3 |
| Target Price | ★ $42.75 | $25.67 |
| AVG Volume (30 Days) | ★ 2.6M | 304.7K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.39% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $270,288,000.00 | N/A |
| Revenue This Year | $18.87 | $9.67 |
| Revenue Next Year | $17.77 | $9.99 |
| P/E Ratio | ★ N/A | $27.15 |
| Revenue Growth | ★ 24.35 | N/A |
| 52 Week Low | $19.70 | $12.89 |
| 52 Week High | $63.90 | $28.00 |
Technical Indicators
Market Signals| Indicator | VRNS | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 72.69 | 61.80 |
| Support Level | $31.28 | $13.58 |
| Resistance Level | $63.90 | $22.00 |
| Average True Range (ATR) | 2.42 | 0.84 |
| MACD | 0.23 | 0.10 |
| Stochastic Oscillator | 77.19 | 88.49 |
Price Performance
Historical ComparisonAbout VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
About STVN Stevanato Group S.p.A.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.